Friday, 20 October 2017

Dr. Reddy's launches antidepressants in the US market

06 September 2017 | News

Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg, is a therapeutic equivalent generic version of Wellbutrin XL (Bupropion Hydrochloride Extended-Release) Tablets.

Courtesy- wikimedia

Courtesy- wikimedia

Dr. Reddy’s Laboratories Ltd. has launched Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg, a therapeutic equivalent generic version of Wellbutrin XL (Bupropion Hydrochloride Extended-Release) Tablets, approved by the U.S. Food & Drug Administration (USFDA). 

Bupropion Hydrochloride Extended-Release Tablets , an antidepressant of the aminoketone class, is chemically unrelated to tricyclic, tetracyclic, selective serotonin re-uptake inhibitor, or other known antidepressant agents. Its structure closely resembles that of diethylpropion; it is related to phenylethylamines.

 The Wellbutrin XL brand and generic had U.S. sales of approximately $754 million MAT for the most recent twelve months ending in July 2017 according to IMS Health.

Dr. Reddy’s Bupropion Hydrochloride Extended-Release Tablets, USP (XL), 150 mg and 300 mg, are each available in bottle count sizes of 30, 90 and 500.

Wellbutrin XL is a trademark of GlaxoSmithKline LLC.

Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account





Survey Box

Is India becoming dependent on imports for key drug intermediates?

× Please select an option to participate in the poll.
Processing...   View poll results   More polls

× You have successfully cast your vote.
{{ optionDetail.option }}{{ optionDetail.percentage }}%
{{ optionDetail.percentage }}% Complete
More polls